|
|
|
|
|
|
|
|
|
|
KEYNOTE SPEAKER: CGMP Requirements for Early Clinical Development: Implication of FDA Guidance Document. Brenda P. Fielding, Regulus Pharmaceutical Consulting, LLC |
|
|
|
|
|
Opening Remarks |
|
|
Development of MALDI-TOF-MS Assays for Preclinical Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses. Scott Warder, Abbott, Inc. |
|
|
Peptide-Based In Vitro Assay for the Detection of Reactive Intermediates. David Thompson, Pfizer, Inc. |
|
|
Lunch (complimentary buffet included with registration fee) |
|
|
Opening Remarks |
|
|
MALDI/MS and MS/MS Analyses as Manufacturing Aids in Peptide Synthesis. John Phipps, Global Peptide Services |
|
|
An Analytical Chemistry Approach to MALDI/ SELDI Experimental Design. Gregory Schneider, EMD Biosciences, Inc. |
|
|
Applications of MALDI/TOF/TOF and LC/MALDI in a University Core Laboratory. Philip Ryan, Colorado State University |
|
|
Closing Remarks |
info@rockychem.com